Am I Entitled to Mounjaro on the NHS?

What NICE concluded and what it means for NHS funding

NICE's appraisal of tirzepatide, TA1026, drew heavily on the SURMOUNT-1 trial: over 2,500 adults with obesity, no diabetes, and an average body-weight reduction of around 20–21% at the highest dose over 72 weeks. That evidence base is why NICE recommended tirzepatide at all. But a strong clinical case doesn't translate automatically into broad NHS entitlement, and if you want to understand how Mounjaro fits into NHS prescribing, it's worth knowing that the guidance restricts funding to adults with a BMI of 35 or above and at least one weight-related comorbidity, implemented in phases to manage NHS capacity.

The phased rollout matters. The first cohort, open from June 2025, covers BMI ≥40 with four or more qualifying conditions. Cohort 2, which activated in June 2026, brings in BMI 35–39.9 with the same four-condition requirement. A third cohort, expected around March 2027, will cover BMI ≥40 with three conditions. Each step is conditional on the previous cohort being managed safely. For a more detailed breakdown of each phase, the NHS Mounjaro rollout timeline covers what's confirmed and what's still projected.

The five qualifying conditions are type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. Holding one or two of those conditions (even with a high BMI) currently falls outside NHS criteria. Every eligible patient must also commit to wrap-around lifestyle support; Mounjaro is not dispensed as a standalone prescription under NHS rules.

Why meeting the criteria doesn't always mean getting it quickly

GP practices can prescribe tirzepatide under the 2026/27 GP contract, but participation is voluntary. Some practices have signed up; others haven't, or are still setting up the required dietary support pathways. NHS England is clear that meeting eligibility criteria does not guarantee access, supply depends on your local Integrated Care Board's readiness, your GP's participation and whether a prescriber judges Mounjaro clinically suitable for you specifically.

Specialist weight management services, which handle Wegovy referrals under a separate NICE appraisal, have their own waiting lists that commonly run to many months. The practical picture for most people right now is that NHS entitlement is limited, conditional and subject to local variation. NHS England's guidance on weight management injections sets this out plainly.

If you're trying to work out whether you currently qualify, the eligibility criteria page walks through the criteria systematically, check whether you meet the NHS eligibility thresholds before approaching your GP, so you go into that conversation knowing the numbers.

What the private route looks like if you don't qualify yet

Private prescribing follows the licensed criteria rather than NHS commissioning criteria. Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That's a considerably lower bar than the NHS currently funds. A clinician working in private practice can prescribe for anyone who meets those licence thresholds and has no clinical contraindications, the Mounjaro treatment overview explains the licence in full.

The cost consideration is real. Private treatment isn't subsidised, and Eli Lilly's UK list price rose substantially from September 2025, market prices now range roughly £149–£375 per month depending on the dose and provider. If you want to understand what drives those figures and what an all-in price actually covers, the Mounjaro cost guide breaks it down without the hidden-fee small print.

At nume, a named prescriber reviews every consultation personally, your answers go to a clinician, not to an automated filter. If approved, your order is dispatched the same day (for consultations completed before midday on a working day), and DPD delivers it the next working day in plain, unbranded packaging. You'll get a tracking link so you know exactly when it'll arrive. There are no subscriptions; every repeat requires a fresh clinical review. If you'd like to explore whether you're suitable, you can speak to our prescribers through a free consultation, no commitment, no fee for the assessment itself.

Ethnic background thresholds and what to tell your GP

Both NHS and private eligibility carry lower BMI thresholds for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Under NICE TA1026, the BMI cut-offs reduce by 2.5 kg/m², so, for example, BMI 37.5 becomes the equivalent of 40 for cohort-one purposes. This applies on the NHS and is recognised in private clinical assessment too.

If you're approaching your GP, it helps to know your exact BMI, your confirmed diagnoses and whether your practice has joined the GP contract for tirzepatide prescribing. Some practices will tell you they can't prescribe it yet, even if you meet the criteria, because they haven't set up the support pathway. That's not a clinical rejection, it's a commissioning gap. The step-by-step guide to requesting Mounjaro on the NHS covers what to say and what documentation to bring. For broader context on the treatment options available alongside Mounjaro, the weight-loss treatments overview is worth reading before your appointment.